Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR 363.40
+6.55 (1.84%)
Sep 5, 2025, 3:29 PM IST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2005 - 2019 |
Biosimilars | 89.29B | Log In | Log In | Log In | Log In | Upgrade |
Biosimilars Growth | 1.26% | Log In | Log In | Log In | Log In | Upgrade |
Research | 35.86B | Log In | Log In | Log In | Log In | Upgrade |
Research Growth | 4.32% | Log In | Log In | Log In | Log In | Upgrade |
Generics | 27.47B | Log In | Log In | Log In | Log In | Upgrade |
Generics Growth | 9.87% | Log In | Log In | Log In | Log In | Upgrade |
Novels | - | Log In | Log In | Log In | Log In | Upgrade |
Novels Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2005 - 2019 |
United States | 70.42B | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 9.10% | Log In | Log In | Log In | Log In | Upgrade |
European Union (including Ireland) | 38.48B | Log In | Log In | Log In | Log In | Upgrade |
European Union (including Ireland) Growth | 9.42% | Log In | Log In | Log In | Log In | Upgrade |
Rest of the World | 33.95B | Log In | Log In | Log In | Log In | Upgrade |
Rest of the World Growth | 6.89% | Log In | Log In | Log In | Log In | Upgrade |
India | 9.77B | Log In | Log In | Log In | Log In | Upgrade |
India Growth | -39.27% | Log In | Log In | Log In | Log In | Upgrade |
Ireland | - | Log In | Log In | Log In | Log In | Upgrade |
Ireland Growth | - | Log In | Log In | Log In | Log In | Upgrade |